Repos Pharma (sponsor), 2020-01-22: Registry record for a Swedish phase 2a trial of individually dose-adjusted mebendazole in advanced gastrointestinal cancer. It lists 11 actual enrollees and was terminated for lack of efficacy.
All patients will be given ReposMBZ for 16 weeks continuous treatment, individually dosed based on the serum concentration of mebendazole.
n/a
Repos Pharma (sponsor), 2020-01-22: Registry record for a Swedish phase 2a trial of individually dose-adjusted mebendazole in advanced gastrointestinal cancer. It lists 11 actual enrollees and was terminated for lack of efficacy. Record field quoted from the brief summary; registry record. Study type: phase 2a, single-arm, therapeutic drug monitoring. N=11 actual. Country: Sweden. Dose: ReposMBZ individualized up to 4 g/day to target serum mebendazole 300 ng/mL, 16 weeks. Sponsor: Repos Pharma. Status: TERMINATED; reason 'lack of efficacy'; start 2018-05-25; completion 2019-01-16. hasResults=false. Comparator: none. Results published by Mansoori et al. 2021 (MBC-12). Registry entry; no results posted.
